Hutchison China MediTech is a biopharmaceutical company, engaging in the research, development, manufacture and sale of pharmaceuticals and healthcare products. It operates through Innovation Platform and Commercial Platform segments. The Company provides drug research and development services and develops, manufactures, distributes, markets and sells prescription and over-the-counter pharmaceutical products, and consumer health products under the Baiyunshan and Shang Yao brands. It also develops clinical drug candidates, including AZD6094 that is in Phase II clinical trial for treating non-small cell lung, colorectal and gastric cancer; Fruquintinib, which is in Phase III clinical trial for the treatment of colorectal, non-small cell lung and gastric cancer; Sulfatinib, a Phase II clinical trial product for neuroendocrine tumors and thyroid cancers; and Epitinib for the treatment of non-small cell lung cancer that is in Phase Ib clinical trial.
Market capitalization (15-Sept-2021)
Closing stock price (15-Sept-2021)
When was Hutchison China Meditech founded?
Hutchison China Meditech was founded in 2000.
Who are Hutchison China Meditech key executives?
Hutchison China Meditech's key executives are Christian Hogg, Johnny Cheng and Wei-Guo Su.
How many employees does Hutchison China Meditech have?
Hutchison China Meditech has 1,280 employees.
Who are Hutchison China Meditech competitors?
Competitors of Hutchison China Meditech include Sygnature Discovery, Moderna and Novartis.
Where are Hutchison China Meditech offices?
Hutchison China Meditech has an office in Florham Park.
How many offices does Hutchison China Meditech have?
Hutchison China Meditech has 4 offices.
Receive alerts for 300+ data fields across thousands of companies